Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Holding TNDM?
Track your performance easily
TNDM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.33 - $53.69
Previous Close$31.37
Volume1.31M
Average Volume (3M)1.27M
Market Cap
$2.06B
Enterprise Value$2.06B
Total Cash (Recent Filing)$473.31M
Total Debt (Recent Filing)$475.95M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Feb 19, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding65,676,532
10 Day Avg. Volume1,822,254
30 Day Avg. Volume1,272,034
Standard Deviation0.18
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)8.59
Price to Sales (P/S)2.41
Price to Cash Flow (P/CF)19.20
P/FCF Ratio23.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.41
Enterprise Value/Gross Profit5.61
Enterprise Value/Ebitda-27.13
Forecast
1Y Price Target
$53.00Price Target Upside70.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Tandem Diabetes Care News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTNDM delivered the highest quarterly sales in its history, both in the US and internationally, with revenue totaling $243M in 3Q versus the $224M consensus.
Growth PotentialTNDM is being assigned little-to-no credit for its ongoing pharmacy migration and expansion in Type 2 patients, along with its future product launches, which represent potentially meaningful growth drivers.
Market DemandThe return to year-over-year new pump growth in the US, with more than half of the shipments to new users, shows strong market demand.
Bears Say
Financial GuidanceManagement's updated 4Q-24 U.S. guidance also suggests a slowing in 4Q y/y domestic growth to ~14-17%.
Market CompetitionThe competitive environment for TNDM is also harsher than it was a few years ago, with MDT's 780G, Beta Bionics' iLet, and PODD's O5 all strong competitors.
Product PerformanceSurvey results suggest more limited MDI share recapture for Mobi than bulls seem to expect.
---
Ownership Overview
0.81% Insiders
34.27% Mutual Funds
16.57% Other Institutional Investors
22.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $14.33 and its highest was $53.69 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Currently, no data Available
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Feb 19, 2025 which is in 90 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Nov 06, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.057.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -$0.21.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 65,676,530 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went down -2.687%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Among the largest hedge funds holding Tandem Diabetes Care’s share is Gilder Gagnon Howe & Co LLC.. It holds Tandem Diabetes Care’s shares valued at 41M.
---
Tandem Diabetes Care Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.00 (70.42% Upside)
$53.00 (70.42% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 269.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.1%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
119.67%
12-Months-Change
Fundamentals
Return on Equity
-45.96%
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
---
TNDM Company Deck
---
TNDM Earnings Call
Q3 2024
0:00 / 0:00
---
TNDM Revenue Breakdown
74.21% U.S.
25.79% International
---
TNDM Stock 12 Month Forecast
Average Price Target
$53.00
▲(70.42% Upside)
Technical Analysis
Best Analysts Covering TNDM
1 Year
1 Year Success Rate
21/28 ratings generated profit
1 Year Average Return
+124.23%
reiterated a buy rating 4 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +124.23% per trade.
---